Disability in patients with multiple sclerosis: Influence of insulin resistance, adiposity, and oxidative stress

Nutrition

Volumn 30, Issue 3, 2014, Pages 268-273

  Oliveira, Sayonara Rangel ^a   Colado Simão, Andréa Name ^a   Kallaur, Ana Paula ^a   Delicato de Almeida, Elaine Regina ^a   Morimoto, Helena Kaminami ^a   Lopes, Josiane ^a   Dichi, Isaias ^a   Kaimen Maciel, Damácio Ramon ^a   Vissoci Reiche, Edna Maria ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

Cytokines; EDSS; Insulin resistance; Multiple sclerosis; Oxidative stress

Indexed keywords

CYTOKINES; EDSS; INSULIN RESISTANCE; MULTIPLE SCLEROSIS; OXIDATIVE STRESS;

ADIPOSITY; ADULT; ANTHROPOMETRY; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-17; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; OBESITY; OXIDATIVE STRESS; PREVALENCE; WAIST CIRCUMFERENCE;

EID: 84893413348     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2013.08.001     Document Type: Article

References (41)

1. Sayre L.M., Perry G., Smith M.A. Oxidative stress and neurotoxicity. Chem Res Toxicol 2008, 21:172-188.
2. Amorini A.M., Petzold A., Tavazzi B., Eikelenboom J., Keir G., Belli A., et al. Increased of uric acid and purine compounds in biological fluids of multiple sclerosis patients. Clin Biochem 2009, 42:1001-1006.
3. Oliveira S.R., Kallaur A.P., Simão A.N., Morimoto H.K., Lopes J., Panis C., et al. Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale. J Neurol Sci 2012, 321:49-53.
4. Amato M.P., Ponziani G., Siracusa G., Sorbi S. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001, 58:1602-1606.
5. Bobholz J.A., Rao S.M. Cognitive dysfunction in multiple sclerosis: a review of recent developments. Curr Opin Neurol 2003, 16:283-288.
6. Watson G.S., Craft S. Insulin resistance, inflammation, and cognition in Alzheimer's Disease: lessons for multiple sclerosis. J Neurol Sci 2006, 245:21-33.
7. Duarte A.I., Moreira P.I., Oliveira C.R. Insulin in central nervous system: more than just a peripheral hormone. J Aging Res 2012, 2012:1-21.
8. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010, 72:219-246.
9. Styskal J., Remmen H.V., Richardson A., Salmon A. Oxidative stress and diabetes: what can we learn about insulin resistance from antioxidant mutant mouse models?. Free Radic Biol Med 2012, 52:46-58.
10. Krogh-Madsen R., Plomgaard P., Keller P., Keller C., Pedersen B.K. Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 2004, 286:E234-E238.
11. Behi M.E., Dubucquoi S., Lefrane C., Zephir H., de Seze J., Vermersch P., et al. New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Lett 2005, 96:11-26.
12. Feinstein D.L., Galea E., Gavrilyuk V., Brosnan C.F., Whitacre C.C., Dumitrescu-Ozimek L., et al. Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol 2002, 51:694-702.
13. Diab A., Deng C., Smith J.D., Hussain R.Z., Phanavanh B., Lovett-Racke A.E., et al. Peroxisome proliferator-activated receptor-gamma agonist 15-deoxy-Delta (12, 14)-prostaglandin J(2) ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002, 168:2508-2515.
14. Marrie R.A., Rudick R., Horwitz R., Cutter G., Tyry T., Campagnolo D., et al. Vascular morbiditiy is associated with more rapid disability progression in multiple sclerosis. Neurology 2010, 74:1041-1047.
15. Weinstock-Guttman B., Zivadinov R., Mahfooz N., Carl E., Drake A., Schneider J., et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation 2011, 8:127.
16. Simão A.N.C., Dichi J.B., Barbosa D.S., Cecchini R., Dichi I. Influence of uric acid and gamma-glutamyltransferase on total antioxidant capacity and oxidative stress in patients with metabolic syndrome. Nutrition 2008, 24:675-681.
17. Lozovoy M.A., Simão A.N., Hohmann M.S., Simão T.N., Barbosa D.S., Morimoto H.K., et al. Inflammatory biomarkers and oxidative stress measurements in patients with systemic lupus erythematosus with or without metabolic syndrome. Lupus 2011, 20:1356-1364.
18. Dichi I., Simão A.N. Metabolic syndrome: new targets for an old problem. Expert Opin Ther Targets 2012, 16:147-150.
19. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
20. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33:1444-1452.
21. Pickering T.G., Hall J.E., Appel L.J., Falkner B.E., Graves J., Hill M.N., et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005, 45:142-161.
22. Haffner S.M., Miettinen H., Stern M.P. The homeostasis model in San Antonio Heart Study. Diabetes Care 1997, 20:1087-1092.
23. Gonzales-Flecha B.G., Llesuy S., Boveris A. Hydroperoxide-initiated chemiluminescence: an assay for oxidative stress in biopsies of heart, liver and muscle. Free Radic Biol Med 1991, 10:93-100.
24. Casado M.F., Cecchini A.L., Simão A.N.C., Oliveira R.D., Cecchini R. Free radical-mediated pre-hemolytic injury in human red blood cells subjected to lead acetate as evaluated by chemiluminescence. Food Chem Toxicol 2007, 45:945-952.
25. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., Capeillère-Blandin C., Nguyen A.T., Canteloup S., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998, 161:2524-2532.
26. Hu M.L. Measurement of protein thiol groups and glutathione in plasma. Methods in enzymology 1994, 380-382. Academic Press, California. J.N. Abelson, M.I. Simon (Eds.).
27. Esteve E., Ricart W., Fernández-Real J.M. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr 2005, 24:16-31.
28. Gonsette R.E. Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. J Neurol Sci 2008, 274:48-53.
29. Moller D.E. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab 2000, 11:212-217.
30. Bastard J.P., Maachi M., Van Nhieu J.T., Jardel C., Bruckert E., Grimaldi A., et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both invivo and invitro. J Clin Endocrinol Metab 2002, 87:2084-2089.
31. Imitola J., Chitnis T., Khoury S.J. Cytokines in multiples sclerosis: from bench to besides. Pharmacol Ther 2005, 106:163-177.
32. Hayakawa T., Nagai Y., Taniguchi M., Yamashita H., Takamura T., Abe T., et al. Tumor necrosis factor-β gene NcoI polymorphism decreases insulin resistance in Japanese men. Metabolism 2000, 49:1506-1509.
33. Aggarwal B.B., Natarajan K. Tumor necrosis factors: developments during the last decade. Eur Cytokine Netw 1996, 7:93-124.
34. Mira J.P., Cariou A., Grall F., Delclaux C., Losser M.R., Heshmati F., et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a Multicenter Study. JAMA 1999, 282:561-568.
35. Cawthorn W.P., Sethi J.K. TNF-α and adipocyte biology. FEBS Lett 2008, 582:117-213.
36. Straczkowski M., Kowalska I., Nikolajuk A., Adamska A., Karolczuk-Zarachowicz M., Karczewska-Kupczewska M., et al. Plasma levels of soluble tumor necrosis factor-α receptors are related to total and LDL-cholesterol in lean, but not in obese subjects. Cardiovasc Diabetol 2006, 5:1-7.
37. Zúñiga L.A., Shen W.J., Joyce-Shaikh B., Pyatnova E.A., Richards A.G., Thom C., et al. IL-17 regulates adipogenesis, glucose homeostasis, and obesity. J Immunol 2010, 185:6947-6959.
38. Brandão C.O., Ruocco H.H., Farias Ados S., Oliveira C., Hallal-Longo D.E., Mirandola S.R., et al. Cytokines and intrathecal IgG synthesis in multiple sclerosis during clinical remission. Arq Neuropsiquiatr 2005, 63:914-919.
39. McGillicuddy F.C., Chiquoine E.H., Hinkle C.C., Kim R.J., Shah R., Roche H.M. Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway. J Biol Chem 2009, 284:31936-31944.
40. Kaneki M., Shimizu N., Yamada D., Chang K. Nitrosative stress and pathogenesis of insulin resistance. Antioxid Redox Signal 2007, 9:319-329.
41. Venturini D., Simão A.N., Scripes N.A., Bahls L.D., Melo P.A., Belinetti F.M., et al. Evaluation of oxidative stress in overweight subjects with or without metabolic syndrome. Obesity (Silver Spring) 2012, 20:2361-2366.